• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Beyond a liver-gut focus: the evolution of gastroenterology and hepatology in challenging the obesity and steatotic liver disease paradigm.

作者信息

Brennan Paul N, Zelber-Sagi Shira, Allen Alina M, Dillon John F, Lazarus Jeffrey V

机构信息

University of Dundee, Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, Dundee, UK.

Department of Gastroenterology, NHS Tayside, Ninewells Hospital and Medical School, Dundee, UK.

出版信息

Gut. 2024 Mar 7;73(4):560-563. doi: 10.1136/gutjnl-2023-330771.

DOI:10.1136/gutjnl-2023-330771
PMID:37898546
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10958288/
Abstract
摘要

相似文献

1
Beyond a liver-gut focus: the evolution of gastroenterology and hepatology in challenging the obesity and steatotic liver disease paradigm.超越肝脏-肠道的关注范畴：胃肠病学和肝病学在挑战肥胖与脂肪性肝病范式中的发展历程
Gut. 2024 Mar 7;73(4):560-563. doi: 10.1136/gutjnl-2023-330771.
2
Metabolic dysfunction-associated steatotic liver disease: Recent turning points for its diagnosis and management.代谢功能障碍相关脂肪性肝病：诊断与管理的近期转折点
Metabolism. 2024 Aug;157:155936. doi: 10.1016/j.metabol.2024.155936. Epub 2024 May 17.
3
Brazilian evidence-based guideline for screening, diagnosis, treatment, and follow-up of metabolic dysfunction-associated steatotic liver disease (MASLD) in adult individuals with overweight or obesity: A joint position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM), Brazilian Society of Hepatology (SBH), and Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso).巴西超重或肥胖成人代谢功能障碍相关脂肪性肝病（MASLD）的筛查、诊断、治疗和随访的循证指南：巴西内分泌学会和代谢学会（SBEM）、巴西肝脏学会（SBH）和巴西肥胖与代谢综合征研究协会（Abeso）的联合立场声明。
Arch Endocrinol Metab. 2023 Nov 27;67(6):e230123. doi: 10.20945/2359-4292-2023-0123.
4
The Future of Nonalcoholic Fatty Liver Disease Treatment.非酒精性脂肪性肝病治疗的未来。
Med Clin North Am. 2019 Jan;103(1):57-69. doi: 10.1016/j.mcna.2018.08.005. Epub 2018 Nov 1.
5
Novel Strategies to Treat Hepatic Steatosis and Steatohepatitis.新型策略治疗肝脂肪变性和脂肪性肝炎。
Obesity (Silver Spring). 2019 Sep;27(9):1385-1387. doi: 10.1002/oby.22559. Epub 2019 Jul 25.
6
[Diagnosis and treatment strategy of pediatric nonalcoholic fatty liver disease].[小儿非酒精性脂肪性肝病的诊断与治疗策略]
Zhonghua Er Ke Za Zhi. 2024 Jun 2;62(6):590-592. doi: 10.3760/cma.j.cn112140-20240326-00213.
7
Nonalcoholic fatty liver disease: a systematic review.非酒精性脂肪性肝病：系统评价。
JAMA. 2015 Jun 9;313(22):2263-73. doi: 10.1001/jama.2015.5370.
8
Time to consider a holistic approach to the treatment of non-alcoholic fatty liver disease in obese young people?是时候考虑采用整体方法来治疗肥胖年轻人的非酒精性脂肪性肝病了吗？
Gut. 2023 Jul;72(7):1238-1239. doi: 10.1136/gutjnl-2022-328316. Epub 2022 Aug 9.
9
Nonalcoholic fatty liver disease (NAFLD) pathophysiology in obese children and adolescents: update.肥胖儿童和青少年非酒精性脂肪性肝病（NAFLD）的病理生理学：最新进展
Nutr Hosp. 2017 Jun 5;34(3):727-730. doi: 10.20960/nh.723.
10
Focusing on the past, present, and future of hepatology.关注肝病学的过去、现在和未来。
J Hepatol. 2014 Dec;61(6):1196-8. doi: 10.1016/j.jhep.2014.08.039. Epub 2014 Sep 6.

引用本文的文献

1
Guideline-directed medical strategies for the co-management of heart failure and metabolic dysfunction-associated steatotic liver disease.心力衰竭与代谢功能障碍相关脂肪性肝病联合管理的指南导向性医学策略。
Commun Med (Lond). 2025 Jul 28;5(1):312. doi: 10.1038/s43856-025-00951-2.
2
A call for doubling the diagnostic rate of at-risk metabolic dysfunction-associated steatohepatitis.呼吁将有风险的代谢功能障碍相关脂肪性肝炎的诊断率提高一倍。
Lancet Reg Health Eur. 2025 Jun 4;54:101320. doi: 10.1016/j.lanepe.2025.101320. eCollection 2025 Jul.
3
Research progress of polysaccharide drug delivery systems in the treatment of intestinal diseases: A review.多糖药物递送系统在肠道疾病治疗中的研究进展：综述
Sci Prog. 2025 Apr-Jun;108(2):368504251353024. doi: 10.1177/00368504251353024. Epub 2025 Jun 27.
4
Sex Disparities in Alcohol-Associated Liver Disease and Subtype Differences in Alcohol-attributable Cancers in the United States.美国酒精性肝病中的性别差异及酒精所致癌症的亚型差异
Clin Mol Hepatol. 2025 Apr 11. doi: 10.3350/cmh.2025.0169.
5
Glucose-Dependent Insulinotropic Polypeptide in Incretin Physiology: Role in Health and Disease.肠促胰岛素生理中的葡萄糖依赖性促胰岛素多肽：在健康与疾病中的作用
Endocr Rev. 2025 Jul 15;46(4):479-500. doi: 10.1210/endrev/bnaf006.
6
Envisioning how to advance the MASH field.展望如何推动 MASH 领域的发展。
Nat Rev Gastroenterol Hepatol. 2024 Oct;21(10):726-738. doi: 10.1038/s41575-024-00938-9. Epub 2024 Jun 4.
7
Letter regarding "Waiting for the changes after the adoption of steatotic liver disease".关于“等待脂肪性肝病采用后的变化”的信件
Clin Mol Hepatol. 2024 Jan;30(1):118-120. doi: 10.3350/cmh.2023.0472. Epub 2023 Nov 14.

本文引用的文献

1
Reply: A multi-society Delphi consensus statement on new fatty liver disease nomenclature.回复：关于新的脂肪性肝病命名的多学会德尔菲共识声明。
Hepatology. 2024 Mar 1;79(3):E93-E94. doi: 10.1097/HEP.0000000000000696. Epub 2023 Nov 20.
2
The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease.酒精性肝病与非酒精性脂肪性肝病的交集。
Nat Rev Gastroenterol Hepatol. 2023 Dec;20(12):764-783. doi: 10.1038/s41575-023-00822-y. Epub 2023 Aug 15.
3
A global action agenda for turning the tide on fatty liver disease.全球行动议程：扭转脂肪肝疾病流行趋势。
Hepatology. 2024 Feb 1;79(2):502-523. doi: 10.1097/HEP.0000000000000545. Epub 2023 Aug 4.
4
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.Retatrutide，一种胰高血糖素样肽-1（GLP-1）和胰高血糖素受体双重激动剂，用于治疗 2 型糖尿病患者：一项在美国进行的随机、双盲、安慰剂和阳性对照、平行组、2 期临床试验。
Lancet. 2023 Aug 12;402(10401):529-544. doi: 10.1016/S0140-6736(23)01053-X. Epub 2023 Jun 26.
5
Prevention of Poor Physical and Mental Health through the Green Social Prescribing Opening Doors to the Outdoors Programme: A Social Return on Investment Analysis.通过绿色社会处方“开门见绿”项目预防身心不良：社会投资回报分析。
Int J Environ Res Public Health. 2023 Jun 12;20(12):6111. doi: 10.3390/ijerph20126111.
6
A global research priority agenda to advance public health responses to fatty liver disease.推进应对脂肪肝疾病的公共卫生措施的全球研究优先事项议程
J Hepatol. 2023 Sep;79(3):618-634. doi: 10.1016/j.jhep.2023.04.035. Epub 2023 Jun 20.
7
Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach.非酒精性脂肪性肝炎的抗纤维化治疗：以人为中心方法的时代。
Nat Rev Gastroenterol Hepatol. 2023 Oct;20(10):679-688. doi: 10.1038/s41575-023-00796-x. Epub 2023 Jun 2.
8
Impact of a social prescribing intervention in North East England on adults with type 2 diabetes: the SPRING_NE multimethod study.英格兰东北部社会处方干预对 2 型糖尿病成人的影响：SPRING_NE 多方法研究。
Public Health Res (Southampt). 2023 Mar;11(2):1-185. doi: 10.3310/AQXC8219.
9
Fatty Liver Disease and Food Insecurity: Excess in Scarcity.脂肪肝疾病与粮食安全：丰饶中的匮乏。
Curr Nutr Rep. 2023 Sep;12(3):439-444. doi: 10.1007/s13668-023-00478-9. Epub 2023 May 29.
10
It is time to expand the fatty liver disease community of practice.是时候扩大脂肪肝疾病实践社群了。
Hepatology. 2023 Nov 1;78(5):1325-1328. doi: 10.1097/HEP.0000000000000411. Epub 2023 Jun 23.